XBIT XBiotech Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1626878 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-49.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-29.9%
ROA-29.0%
ROIC (approx.)-193.7%
Asset turnover—
Leverage & solvency
Liabilities / assets3.5%
Debt / equity0.00x
Current ratio39.51x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.94x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $47.39M | $37.76M |
| SG&A expense | $8.29M | $4.71M |
| Operating income | -$55.69M | -$42.47M |
| Pretax income | -$45.30M | -$38.56M |
| Income tax | $235,000 | -$32,000 |
| Net income | -$45.54M | -$38.53M |
| EBITDA | -$54.00M | -$40.73M |
| EPS (basic) | -1.49 | -1.26 |
| EPS (diluted) | -1.49 | -1.26 |
| Weighted avg. shares (diluted) | 30.49M | 30.46M |
| Balance sheet | ||
| Cash & equivalents | $125.55M | $172.68M |
| Receivables | — | $700,000 |
| Current assets | $126.95M | $174.57M |
| PP&E, net | $23.13M | $24.53M |
| Total assets | $150.08M | $199.09M |
| Current liabilities | $7.93M | $15.11M |
| Total liabilities | $9.73M | $16.82M |
| Shareholders' equity | $140.35M | $182.27M |
| Shares outstanding | 30.49M | 30.49M |
| Cash flow statement | ||
| Operating cash flow | -$39.92M | -$30.96M |
| Capital expenditure | $289,000 | $1.30M |
| Free cash flow | -$40.21M | -$32.27M |
| Investing cash flow | -$289,000 | -$1.30M |
| Financing cash flow | -$10.25M | $10.45M |
| Depreciation & amortization | $1.69M | $1.75M |
| Stock-based compensation | $3.62M | $1.75M |
| Share buybacks | — | $0 |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.